SCHEMBL1937652

SCHEMBL1937652

CN[C@@H]1CN(C(=O)c2ccccc2)C[C@@H]1c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR2 O60603 8/20 0.53
TLR1 Q15399 7/20 0.53
CCR5 P51681 2/20 0.49
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
RECQL P46063 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MGLL Q99685 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
MC4R P32245 1/20 0.44
POLB P06746 1/20 0.44
PLA2G1B P04054 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7921209 1.00 TLR2 (0.53) TLR2TLR1CCR5CYP1A2CYP3A4
SCHEMBL2799214 1.00 TLR2 (0.53) TLR2TLR1CCR5CYP1A2CYP3A4
SCHEMBL7932432 0.80 LMNA (0.49) TLR2TLR1CYP1A2CYP3A4CYP2C9
SCHEMBL2797980 0.80 LMNA (0.49) TLR2TLR1CYP1A2CYP3A4CYP2C9
SCHEMBL1938358 0.80 LMNA (0.49) TLR2TLR1CYP1A2CYP3A4CYP2C9
SCHEMBL1972533 0.74 TLR2 (0.43) TLR2TLR1MEN1KMT2A
SCHEMBL1969431 0.74 TLR2 (0.43) TLR2TLR1MEN1KMT2A
SCHEMBL13229941 0.73 EPHX2 (0.51) TLR2TLR1MEN1KMT2ALMNA
SCHEMBL16565830 0.73 CHRNB2 (0.56) MEN1KMT2AALDH1A1PLA2G1BATG4B
SCHEMBL12281756 0.72 TACR3 (0.46) MEN1KMT2AALDH1A1LMNAMC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293770-B2 Pyrrolidine derivatives as NK-3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-10-23 US disclosed
EP-2331500-A1 PYRROLIDINE N-BENZYL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-06-15 EP disclosed
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 US disclosed
WO-2010040663-A1 PYRROLIDINE N-BENZYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS OPRK1, OPRL1, OPRD1 TLR2 327/4885TLR1 213/4885CCR5 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.